While looking at the Stock's Performance, Esperion Therapeutics, Inc. now shows a Weekly Performance of -23.89%, where Monthly Performance is 13.36%, Quarterly performance is 92.6%, 6 Months performance is 110.59% and yearly performance percentage is 64.6%. Edge Therapeutics, Inc. has a 52-week low of 6.52 and a 52-week high of 13.50. The stock had previously closed at $23.67.
A number of other research firms have also recently commented on ESPR.
05/09/2016 - Edge Therapeutics, Inc. had its "outperform" rating reiterated by analysts at Credit Suisse. Royal Bank of Canada restated a "hold" rating and issued a $15.00 price objective on shares of Esperion Therapeutics in a research report on Tuesday, January 3rd. Zacks Investment Research upgraded shares of Esperion Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, March 2nd.
The 10 analysts offering 12-month price forecasts for Esperion Therapeutics Inc have a median target of 29.50, with a high estimate of 45.00 and a low estimate of 20.00. Stock has got OUTPERFORM rating from 2 analysts of Thomson Reuters, 5 analysts given HOLD rating to the stock and 0 given UNDERPERFORM rating. The price-to-book ratio (P/B Ratio) is a ratio used to compare a stock's market value to its book value.
Bill Gates Tops World Rich List Again While Trump Falls 220 Spots
The rich are getting richer, and if you don't believe us just check out Forbes.com's new list of the world's billionaires. The combined fortunes of this year's billionaires totaled to $7.67 trillion, up from $6.48 trillion in 2016.
It seems all was forgiven today when Esperion, which has nothing to sell but its own shares, provided a detailed timeline that ends with a new drug application. Advisor Group Inc. now owns 14,437 shares of the biopharmaceutical company's stock valued at $200,000 after buying an additional 85 shares during the last quarter. They now have a United States dollars 33 price target on the stock. Senzar Asset Management LLC bought a new position in shares of Esperion Therapeutics during the fourth quarter worth $4,557,000. (NASDAQ:EDGE) was down -2.13% during the last day of trading, with a day high of 8.83. Dimensional Fund Advisors LP increased its position in Esperion Therapeutics by 54.9% in the fourth quarter. The company's market cap is $14.48 Million, and the average volume is $1.04 Million.
Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Wednesday, February 22nd. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.61) by $0.04. During the same period in the prior year, the company earned ($0.53) EPS.
02/22/2017 - Aegis Capital began new coverage on TG Therapeutics, Inc. giving the company a "buy" rating.
TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. Its lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study.